Daniel R Agarwal, MD
Ophthalmology · San Luis Obispo
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · San Luis Obispo Eye Associates, A Medical Group Inc. · Elite Eyecare Medical Group A Medical Corporation
Looking this up.
Hospitals listed: Marian Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Agarwal’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A168859 · Current
Licensed to practise in California · since 2020 · expires 2028-05-31 · Cornell University Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Marian Regional Medical CenterSanta Maria, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 68% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.67 (0.37 to 0.96), Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.081, Oct 2024 – Sep 2025
See every measure and the patient survey for Marian Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.67 (0.37 to 0.96) | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.081 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.99 (0.06 to 1.93) · 1,191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 189.73 (139.29 to 240.17) · 66 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.7 · 103 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 15.9 · 247 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 478 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 470 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 237 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 3,050 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 8,823 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.05 to 0.42) · 8,672 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.87 (0.97 to 4.76) · 2,024 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.12 (0.57 to 3.67) · 782 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.29 (0.85 to 3.72) · 1,934 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 3.63 (0 to 9.97) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.01 (1.37 to 8.65) · 748 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.88 (0.43 to 3.32) · 373 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.13 (0 to 0.73) · 6,968 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 179 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.245 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.85 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.952 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.687 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 198 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 469 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.8 · 232 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.8 · 541 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8.6 · 473 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 434 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.6 (5 to 8.4) · 519 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.9 (8.8 to 13.4) · 519 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.3 · 83 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.2 to 17) · 124 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 638 cases | No different | Jan 2024 – Dec 2024 |
What patients said (666 patients answered, 17% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 64% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$2,349,571
Medicare paid this office $2,349,571 for 1,045 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, faricimab-svoa, 0.1 mg | 131 | $1,199,775 | None |
| Injection, aflibercept, 1 mg | 58 | $414,770 | None |
| Return visit (30+ min) | 960 | $181,070 | $94 |
| Injection of drug into eye | 229 | $119,919 | $89 |
| Imaging of retina | 1,024 | $86,473 | $31 |
See all 16 services
| Injection, faricimab-svoa, 0.1 mg | 131 | $1,199,775 | None |
| Injection, aflibercept, 1 mg | 58 | $414,770 | None |
| Return visit (30+ min) | 960 | $181,070 | $94 |
| Injection of drug into eye | 229 | $119,919 | $89 |
| Imaging of retina | 1,024 | $86,473 | $31 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 182 | $25,687 | $136 |
| Removal of membrane of retina | 15 | $14,714 | $920 |
| New patient visit (45+ min) | 76 | $8,948 | $118 |
| Compounded drug, not otherwise classified | 32 | $5,906 | None |
| Short return visit (20+ min) | 81 | $5,532 | $61 |
| Long return visit (40+ min) | 24 | $3,334 | $128 |
| Photography of the retina | 56 | $1,566 | $27 |
| 2d ultrasound scan of eye tissue and structures | 31 | $1,549 | $38 |
| Extended exam of the back part of the eye with retinal drawing | 46 | $874 | $18 |
| Exam of visual field with extended testing | 11 | $498 | $45 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 36 | $474 | $13 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
1,045 Original Medicare patients in 2024. Average age 77 · Under 65 2% · 85 and older 19% · Women 58% · Also on Medicaid 13% · Health risk score 1.24. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 73% · Diabetes 30% · Chronic kidney disease 22% · Coronary heart disease 21% · Atrial fibrillation 19% · Cancer 15% · Depression 15% · Heart failure 13% · COPD 11% · Stroke 8% · Dementia 6%.
The office billed $4,447,684, Medicare allowed $3,003,326 and paid $2,349,571; for 52,287 services of 49 kinds; $1,822,458 of it was for drugs given in the office and $527,113 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,045 | 52,287 | 77 | 1.24 | $4,447,684 | $2,349,571 |
| 2023 | 915 | 39,576 | 77 | 1.13 | $4,420,715 | $2,409,396 |
| 2022 | 716 | 11,159 | 78 | 1.12 | $3,122,537 | $1,867,267 |
| 2021 | 560 | 2,702 | 74 | 1.55 | $805,835 | $294,205 |
| 2020 | 366 | 1,114 | 72 | 1.77 | $309,049 | $98,425 |
| 2019 | 92 | 128 | 70 | 2.67 | $65,894 | $10,918 |
| 2018 | 42 | 62 | 75 | 1.63 | $37,892 | $4,992 |
| 2017 | 18 | 27 | 75 | 1.83 | $13,197 | $1,539 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 20 services
| Injection, faricimab-svoa, 0.1 mg | 95 | $887,300 | None |
| Injection, aflibercept, 1 mg | 110 | $853,426 | None |
| Return visit (30+ min) | 757 | $153,688 | $101 |
| Injection of drug into eye | 235 | $131,590 | $91 |
| Injection, ranibizumab, 0.1 mg | 21 | $104,149 | None |
| Imaging of retina | 877 | $92,697 | $33 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 209 | $26,240 | $120 |
| Short return visit (20+ min) | 334 | $25,423 | $61 |
| Removal of membrane of retina | 16 | $15,269 | $954 |
| New patient visit (45+ min) | 84 | $10,280 | $122 |
| Compounded drug, not otherwise classified | 40 | $8,382 | None |
| Removal of eye fluid | 14 | $4,657 | $97 |
| Photocoagulation treatment to prevent detachment of retina | 15 | $3,129 | $209 |
| Photography of the retina | 89 | $2,996 | $30 |
| Long return visit (40+ min) | 21 | $2,807 | $134 |
| New patient visit (60+ min) | 11 | $1,861 | $169 |
| Extended exam of the back part of the eye with retinal drawing | 65 | $1,300 | $19 |
| Injection, bevacizumab, 10 mg | 16 | $1,077 | None |
| 2d ultrasound scan of eye tissue and structures | 18 | $1,073 | $38 |
| Exam of visual field with extended testing | 16 | $760 | $48 |
2022: 18 services
| Injection, aflibercept, 1 mg | 146 | $1,051,803 | None |
| Injection, ranibizumab, 0.1 mg | 38 | $197,319 | None |
| Unclassified biologics | 24 | $117,548 | None |
| Injection of drug into eye | 204 | $109,803 | $96 |
| Injection, faricimab-svoa, 0.1 mg | 26 | $102,087 | None |
| Short return visit (20+ min) | 524 | $73,026 | $76 |
| Imaging of retina | 683 | $70,187 | $35 |
| Return visit (30+ min) | 365 | $51,122 | $104 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 141 | $17,618 | $110 |
| Removal of eye fluid | 11 | $4,889 | $100 |
| Long return visit (40+ min) | 21 | $3,188 | $145 |
| New patient visit (45+ min) | 26 | $3,139 | $121 |
| Injection, bevacizumab, 10 mg | 17 | $2,896 | None |
| Established patient complete exam of visual system | 24 | $2,365 | $99 |
| Photography of the retina | 57 | $2,183 | $31 |
| Compounded drug, not otherwise classified | 13 | $1,624 | None |
| 2d ultrasound scan of eye tissue and structures | 17 | $1,159 | $41 |
| Extended exam of the back part of the eye with retinal drawing | 48 | $947 | $20 |
2021: 14 services
| Injection, aflibercept, 1 mg | 18 | $113,910 | None |
| Established patient complete exam of visual system | 310 | $30,441 | $87 |
| Imaging of retina | 498 | $29,319 | $34 |
| Return visit (30+ min) | 201 | $26,304 | $106 |
| Injection of drug into eye | 64 | $25,643 | $100 |
| Short return visit (20+ min) | 140 | $14,759 | $79 |
| Compounded drug, not otherwise classified | 54 | $12,572 | None |
| Destruction of leaking blood vessels of retina using laser | 20 | $12,397 | $302 |
| New patient complete exam of visual system | 45 | $4,923 | $109 |
| Established patient problem focused exam of visual system | 48 | $4,356 | $78 |
| New patient visit (45+ min) | 33 | $4,247 | $129 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 26 | $2,807 | $108 |
| Photography of the retina | 55 | $2,110 | $31 |
| 2d ultrasound scan of eye tissue and structures | 18 | $970 | $42 |
2020: 9 services
| Established patient complete exam of visual system | 286 | $39,311 | $107 |
| Imaging of retina | 316 | $13,801 | $35 |
| New patient complete exam of visual system | 65 | $8,086 | $124 |
| Injection of drug into eye | 34 | $5,114 | $87 |
| Compounded drug, not otherwise classified | 26 | $3,534 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 16 | $1,532 | $96 |
| Established patient problem focused exam of visual system | 13 | $1,203 | $80 |
| Photography of the retina | 29 | $1,128 | $38 |
| Extended exam of the back part of the eye with retinal drawing | 30 | $885 | $22 |
2019: 3 services
| Established patient complete exam of visual system | 15 | $1,631 | $109 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 16 | $1,371 | $86 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 28 | $1,028 | $33 |
2018: 1 service
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $979 | $82 |
2017: 1 service
| Injection of drug into eye | 12 | $965 | $80 |
Medicaid work
$56,309 in 2024
Medicaid paid $56,309 for 566 billed services this clinician did in 2024, up to 39 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 143 | $40,335 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 273 | $7,318 |
| Return visit (30+ min) | 97 | $4,466 |
| Injection, bevacizumab, 10 mg | 53 | $4,190 |
| 2024 | 566 | 4 | 39 | $56,309 |
| 2023 | 874 | 4 | 35 | $85,261 |
| 2022 | 47 | 1 | 18 | $565 |
| 2021 | 793 | 8 | 51 | $64,707 |
| 2020 | 353 | 5 | 39 | $24,810 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 235 | $67,433 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 418 | $9,579 |
| Return visit (30+ min) | 182 | $5,234 |
| Injection, bevacizumab, 10 mg | 39 | $3,015 |
2022
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 47 | $565 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 121 | $30,666 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 363 | $13,152 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 119 | $8,797 |
| Compounded drug, not otherwise classified | 68 | $5,188 |
| Return visit (30+ min) | 52 | $3,358 |
| Short return visit (20+ min) | 43 | $2,018 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 15 | $1,029 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 12 | $500 |
2020
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 141 | $14,126 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 158 | $5,943 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 26 | $2,527 |
| Compounded drug, not otherwise classified | 16 | $1,477 |
| IP/OBS CONSLTJ NEW/EST PT LOW MDM 45 MINUTES | 12 | $736 |
Drugs they prescribed that Part D paid
$30,744
Pharmacies billed $30,744 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 594) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
375 generic and 219 brand-name prescriptions · $30,744 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 124 | $4,760 | $38 |
| Difluprednate | 22 | $3,211 | $146 |
| Bromfenac | 13 | $2,347 | $181 |
| Ketorolac Tromethamine | 80 | $1,640 | $20 |
| Moxifloxacin | 50 | $1,050 | $21 |
See all 12 drugs
| Prednisolone Acetate | 124 | $4,760 | $38 |
| Difluprednate | 22 | $3,211 | $146 |
| Bromfenac | 13 | $2,347 | $181 |
| Ketorolac Tromethamine | 80 | $1,640 | $20 |
| Moxifloxacin | 50 | $1,050 | $21 |
| Dorzolamide-Timolol | 53 | $922 | $17 |
| Atropine Sulfate | 21 | $669 | $32 |
| Latanoprost | 55 | $520 | $9 |
| Timolol Maleate | 11 | $292 | $27 |
| Neomycin-Polymyxin-Dexameth | 31 | $287 | $9 |
| Brimonidine | 34 | $253 | $7 |
| Erythromycin | 11 | $145 | $13 |
Year by year
| 2024 | 594 | 165 | 0% (0) | 37% | $30,744 |
| 2023 | 570 | 154 | 0% (0) | 42% | $40,538 |
| 2022 | 336 | 121 | 0% (0) | 46% | $28,353 |
| 2021 | 496 | 122 | 0% (0) | 41% | $50,838 |
| 2020 | 193 | 78 | 0% (0) | 52% | $19,324 |
| 2019 | 99 | 35 | None | 71% | $12,962 |
| 2018 | 57 | 24 | 0% (0) | 65% | $4,692 |
| 2017 | 15 | None | 0% (0) | 93% | $5,382 |
| 2016 | 39 | 12 | None | 64% | $5,802 |
| 2015 | 20 | None | 0% (0) | None | $1,621 |
| 2014 | 28 | None | 0% (0) | None | $1,381 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Prednisolone Acetate | 136 | $6,610 | $49 |
| Ketorolac Tromethamine | 84 | $1,771 | $21 |
| Moxifloxacin | 44 | $1,472 | $33 |
| Atropine Sulfate | 31 | $1,380 | $45 |
| Dorzolamide-Timolol | 44 | $1,263 | $29 |
| Latanoprost | 44 | $1,209 | $27 |
| Neomycin-Polymyxin-Dexameth | 38 | $586 | $15 |
| Brimonidine | 31 | $339 | $11 |
| Timolol Maleate | 14 | $258 | $18 |
| Erythromycin | 11 | $162 | $15 |
2022: 9 drugs
| Prednisolone Acetate | 81 | $3,124 | $39 |
| Ketorolac Tromethamine | 46 | $1,163 | $25 |
| Atropine Sulfate | 25 | $1,161 | $46 |
| Dorzolamide-Timolol | 22 | $881 | $40 |
| Latanoprost | 27 | $785 | $29 |
| Moxifloxacin | 15 | $452 | $30 |
| Neomycin-Polymyxin-Dexameth | 30 | $438 | $15 |
| Timolol Maleate | 16 | $189 | $12 |
| Brimonidine | 13 | $119 | $9 |
2021: 13 drugs
| Restasis | 13 | $16,412 | $1,262 |
| Combigan | 21 | $5,261 | $251 |
| Durezol | 23 | $4,834 | $210 |
| Prednisolone Acetate | 65 | $2,850 | $44 |
| Latanoprost | 77 | $1,806 | $23 |
| Dorzolamide-Timolol | 48 | $1,653 | $34 |
| Dexamethasone Sodium Phosphate | 19 | $959 | $50 |
| Atropine Sulfate | 15 | $627 | $42 |
| Ketorolac Tromethamine | 18 | $436 | $24 |
| Moxifloxacin | 12 | $405 | $34 |
| Timolol Maleate | 31 | $392 | $13 |
| Brimonidine | 38 | $293 | $8 |
| Dorzolamide | 15 | $220 | $15 |
2020: 5 drugs
| Durezol | 12 | $2,392 | $199 |
| Prednisolone Acetate | 36 | $1,393 | $39 |
| Ketorolac Tromethamine | 22 | $611 | $28 |
| Timolol Maleate | 13 | $216 | $17 |
| Latanoprost | 13 | $169 | $13 |
2019: 1 drug
| Prednisolone Acetate | 19 | $613 | $32 |
2018: 1 drug
| Prednisolone Acetate | 12 | $481 | $40 |
2016: 1 drug
| Brimonidine | 16 | $2,962 | $185 |
Money from drug and device companies
$420 in 2025
| 2025 | 3 | 12 | None | $420 |
| 2024 | 7 | 23 | $2,300 | $3,270 |
| 2023 | 7 | 20 | None | $953 |
| 2022 | 5 | 18 | None | $624 |
| 2021 | 6 | 16 | $1,271 | $2,393 |
| 2020 | 4 | 7 | $1,978 | $2,290 |
| 2019 | 2 | 6 | None | $1,564 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Eylea Hd | $251 | 5 payments
|
| Genentech USA | Vabysmo | $110 | 4 payments
|
| Astellas Pharma US | Izervay | $59 | 3 payments
|
See all 12 published payments
| Astellas Pharma US | Meals · 2025-12-11 | Izervay | $18 |
| Astellas Pharma US | Meals · 2025-11-11 | Izervay | $20 |
| Genentech USA | Meals · 2025-10-30 | Vabysmo | $40 |
| Regeneron Healthcare Solutions | Meals · 2025-09-22 | Eylea Hd | $36 |
| Genentech USA | Meals · 2025-09-18 | Vabysmo | $31 |
| Astellas Pharma US | Meals · 2025-08-25 | Izervay | $21 |
| Regeneron Healthcare Solutions | Meals · 2025-08-21 | Eylea Hd | $25 |
| Genentech USA | Meals · 2025-07-24 | Vabysmo | $15 |
| Regeneron Healthcare Solutions | Meals · 2025-06-09 | Eylea Hd | $26 |
| Regeneron Healthcare Solutions | Meals · 2025-03-17 | Eylea Hd | $39 |
| Genentech USA | Meals · 2025-03-13 | Vabysmo | $24 |
| Regeneron Healthcare Solutions | Meals · 2025-02-13 | Eylea Hd | $125 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,270
| Genentech USA | Vabysmo | $2,701 | 10 payments
|
| Regeneron Healthcare Solutions | Eylea | $245 | 8 payments
|
| Glaukos | Idose | $133 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $119 | 1 payment
|
| Dompe US | Oxervate | $28 | 1 payment
|
| Astellas Pharma US | Izervay | $23 | 1 payment
|
| Alimera Sciences | Yutiq | $19 | 1 payment
|
2023: $953
| Regeneron Healthcare Solutions | Eylea Hd | $310 | 4 payments
|
| Genentech USA | Vabysmo | $248 | 10 payments
|
| AbbVie | Durysta | $123 | 1 payment
|
| Astellas Pharma US | None | $121 | 1 payment
|
| Glaukos | None | $84 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $44 | 2 payments
|
| Regeneron Pharmaceuticals | Eylea | $24 | 1 payment
|
2022: $624
| Genentech USA | Vabysmo | $224 | 12 payments
|
| Apellis Pharmaceuticals | None | $209 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea | $145 | 2 payments
|
| EyePoint Pharmaceuticals US | Dexycu | $24 | 1 payment
|
| Novo Nordisk | Rybelsus | $21 | 1 payment
|
2021: $2,393
| Allergan | Ozurdex | $1,345 | 3 payments
|
| Alcon Vision | Clareon | $436 | 3 payments
|
| Regeneron Healthcare Solutions | Eylea | $335 | 5 payments
|
| Novartis Pharmaceuticals | Beovu | $125 | 1 payment
|
| Sun Pharmaceutical Industries | Cequa | $117 | 2 payments
|
| Kala Pharmaceuticals | Inveltys | $35 | 2 payments
|
2020: $2,290
| Allergan | Ozurdex | $2,118 | 4 payments
|
| Glaukos | Istent Inject Trabecular Micro-Bypass Stent System | $123 | 1 payment
|
| Kala Pharmaceuticals | Inveltys | $24 | 1 payment
|
| Alcon Vision | Acrysof Iq Panoptix | $24 | 1 payment
|
2019: $1,564
| Regeneron Pharmaceuticals | None | $1,541 | 5 payments
|
| Alcon Vision | Acrysof | $24 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 87.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1811230766
- Licence
- CA A168859, CT 60486, OH 35.130547California A168859: Current · expires 2028-05-31
- Trained
- Js Weill Medical College, Cornell University, 2013
- Group
- San Luis Obispo Eye Associates, A Medical Group Inc. · Elite Eyecare Medical Group A Medical Corporation
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X); Student in a training program (390200000X)
- Mailing address
- 689 Tank Farm Rd Ste 100, San Luis Obispo, CA, 93401
- NPI first listed
- 2013-03-28
- NPI last updated
- 2023-04-07
- NPI record certified
- 2023-04-07
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1901 Solar Dr Ste 155, Oxnard, CA, 93036 · 910 E Stowell Rd, Santa Maria, CA, 93454 · 3085 Loma Vista Rd, Ventura, CA, 93003